BNTXBioNTech SE
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$78.3M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -82% · now 19% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BNTX take a bad year?
The deepest fall in BNTX's price history on file is −82%; it is 19% below its high today.
Worst drawdown on file · −19% today
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 49%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $14.9B
- EBITDA, trailing twelve months
- −$1.35B
- Operating profit, trailing twelve months
- −$1.40B
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −82%
- Below its 52-week high
- 19%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.